Clinical Trials
22
7 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
2021
Active, not recruiting
5
22.7%
Completed
9
40.9%
Not yet recruiting
2
9.1%
Recruiting
5
22.7%
Terminated
1
4.5%
No approval data available
- Foresite Labs has appointed Dr. Jorge Reis-Filho as Chief Strategy Officer and Operating Partner, with a concurrent role as Venture Partner at Foresite Capital. - Dr. Reis-Filho joins from AstraZeneca, where he served as Chief of AI for Science Innovation, Enterprise AI, leading AI initiatives to transform drug discovery and clinical development. - His appointment aims to translate advances in AI, machine learning, statistical genetics, and data science into new companies and platforms at the convergence of AI and life sciences. - Dr. Reis-Filho articulates a roadmap from AI agents to "AI innovators" and ultimately biomedical superintelligence, emphasizing validated discovery over retrieval and prediction.
- Alumis Inc. will report topline data from the Phase 3 ONWARD clinical program evaluating envudeucitinib in patients with moderate-to-severe plaque psoriasis on January 6, 2026. - The company will host a conference call and webcast at 8:00 a.m. ET following the data announcement to discuss the results with investors and stakeholders. - Envudeucitinib is an oral tyrosine kinase 2 inhibitor being developed for systemic immune-mediated disorders including plaque psoriasis and systemic lupus erythematosus. - Alumis is a late-stage biopharma company developing next-generation targeted therapies for immune-mediated diseases using a proprietary data analytics platform and precision approach.
- Alumis completed an upsized public offering of 17.65 million shares at $17 per share, raising approximately $300 million in gross proceeds to fund its clinical-stage pipeline. - The company is simultaneously pursuing a merger with ACELYRIN that would create a combined entity with approximately $737 million in pro forma cash and runway into 2027. - The merged company will focus on immune-mediated diseases with key milestones including Phase 3 data for ESK-001 in psoriasis expected in Q1 2026 and Phase 2b lupus data in 2026. - Alumis stockholders will own 55% of the combined company while ACELYRIN stockholders will receive 0.4274 Alumis shares for each ACELYRIN share owned.
- Drug Hunter, a knowledge platform serving over 200 pharmaceutical R&D organizations including Eli Lilly, Biogen, and NIH, announced seed funding led by Teamworthy Ventures to accelerate drug discovery insights. - The platform provides searchable insights from scientific literature, patents, and early disclosures, helping researchers make better-informed decisions and avoid costly mistakes in drug development. - Industry leaders from Isomorphic Labs, Biogen, and other major organizations describe Drug Hunter as an indispensable tool for accelerating decision-making and surfacing novel ideas. - The funding will support expanded scientific coverage, enhanced chemical structure databases, improved search analytics tools, and development of a mobile application for immediate disclosure highlights.
- DelveInsight's 2025 Psoriasis Pipeline Report reveals over 80 companies developing 80+ pipeline therapies, highlighting significant R&D investment in this therapeutic area. - Promising treatments in development include topical roflumilast (Arcutis Biotherapeutics) in Phase III trials and GSK2982772 (GlaxoSmithKline), a novel RIPK1 inhibitor in Phase I development. - Alumis Inc. has initiated a long-term extension study for ESK-001 in moderate to severe plaque psoriasis patients, evaluating safety, efficacy, and durability of response over 24 weeks.
- Alumis will showcase long-term safety and efficacy data for ESK-001, their oral TYK2 inhibitor, in moderate-to-severe plaque psoriasis through multiple presentations at the 2025 AAD annual meeting. - The company has accelerated the timeline for their Phase 3 ONWARD program, with topline data now expected in Q1 2026, reflecting strong patient enrollment and investigator interest. - ESK-001 demonstrated sustained PASI score improvements and favorable safety profile in interim 28-week open-label extension data, with most patients achieving PASI 75 at the 40mg twice-daily dose.
• Alumis and Acelyrin have entered into a merger agreement, marking a significant consolidation in the biotechnology sector. • The companies announced the suspension of the planned Phase III program for lonigutamab following disappointing Phase II results reported in January. • The merger decision includes a strategic reassessment of lonigutamab's development program to evaluate its potential value and future direction.
- Alumis and Acelyrin have agreed to merge in an all-stock transaction, creating a combined entity with $737 million in cash runway extending into 2027. - The merged company will retain the Alumis name and prioritize development of two TYK2 inhibitors targeting conditions including psoriasis, lupus, and multiple sclerosis. - Acelyrin's thyroid eye disease drug lonigutamab is included in the deal but will undergo strategic review to assess its market differentiation potential.
- Alumis' A-005, a selective TYK2 inhibitor, demonstrates successful blood-brain barrier penetration in a Phase 1 trial with healthy subjects. - The trial confirms A-005's safety, tolerability, and favorable pharmacokinetics, showing significant drug exposure in the cerebral spinal fluid. - A-005 achieves maximal TYK2 inhibition in the periphery, with drug levels in CSF comparable to or exceeding those in plasma. - Alumis plans to advance A-005 to a Phase 2 clinical trial for multiple sclerosis in the second half of 2025.
- Alumis Inc. announced positive 28-week data from the open-label extension of its Phase 2 STRIDE trial of ESK-001 for moderate-to-severe plaque psoriasis. - The data showed that 93% of patients on the 40 mg twice-daily dose achieved PASI 75, demonstrating sustained efficacy over time. - ESK-001 continued to exhibit a favorable safety profile, with most treatment-emergent adverse events being mild to moderate. - Alumis expects to report full 52-week OLE data in the first half of 2025 and is advancing ESK-001 in the Phase 3 ONWARD clinical program.
